![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_122,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/SonomaEye-full-color-vector%5B2%5D.png)
Anatomical Subtype Stratification for Evaluating the Safety and Efficacy of CLS-TA in Noninfectious Uveitis-Related Macular Edema: Insights from the P
Presenter:
Milan Shah
Authors:
Milan Shah, Quan Nguyen, Christopher R Henry
1. Ophthalmology, Midwest Eye Institute, Carmel, Indiana, USA
2. Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA
3. Retina Consultants of Texas, Houston, TX, USA.
Affiliation:
Purpose: This study investigates the effectiveness of CLS-TA, a proprietary suprachoroidal injectable suspension of triamcinolone acetonide, in treating macular edema (ME) associated with noninfectious uveitis (NIU), categorized by distinct anatomic subtypes.
Methods: The phase 3 PEACHTREE trial enrolled patients with ME linked to NIU of any etiology and anatomic subtype. Post-hoc analyses were conducted, stratifying participants based on the specific anatomic subtype of uveitis (anterior, intermediate, posterior, and panuveitis).
Results: Over 24 weeks, patients administered CLS-TA at baseline and week 12 exhibited notable improvements across all anatomic subtypes. Mean increases in best-corrected visual acuity (BCVA) ranged from +12.1 to +15.9 letters, central subfield thickness (CST) showed improvement ranging from −120.1 μm to −189.0 μm, and intraocular pressure (IOP) changes ranged from +0.5 to +3.1 mmHg. Overall, adverse event reports were consistent across subtypes.
Conclusion: Regardless of the uveitic anatomic subtype, individuals treated with CLS-TA for ME associated with NIU demonstrated clinical benefits, accompanied by a comparable safety profile.